SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (3665)1/25/1998 5:53:00 PM
From: David S.  Respond to of 6136
 
mister, hey mister - yeaah, you - It is not my fault that Thymitaq was garbage. If it will help heal your pain, then, OK, it was my fault, and my responsibility. You should all blame me. I am worthless, I am trash, I am nothing, all I feel is our existential pain.



To: JOHN W. who wrote (3665)1/26/1998 12:27:00 AM
From: JOHN W.  Read Replies (1) | Respond to of 6136
 
D.S.::

Thymitaq is not garbage..

Better close that position since a critical study relating to the effectiveness of a competings' drugs ability to cross the Blood Brain Barrier (as measured by the VL in spinal fluid) failed miserably compared to Indinavir, (no info on Nelf).


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News